Expression and distribution of MMPs and TIMPs in human uveal melanoma

Experimental Eye Research

Volumn 86, Issue 6, 2008, Pages 936-941

  Lai, K ^a   Conway, R M ^a   Crouch, R ^b   Jager, M J ^c   Madigan, M C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

immunohistochemistry; leukocytes; MMPs; TIMPs; tumour scleral interface; uveal melanoma; vasculature

Indexed keywords

ENZYME ANTIBODY; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 19; PARAFFIN; PEROXIDASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ADULT; AGED; ANTIBODY LABELING; ARTICLE; CANCER GROWTH; CELL STRUCTURE; CELL TYPE; CHOROID; CONTROLLED STUDY; ENZYME SPECIFICITY; EPITHELIOID CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOMA CELL; MICROENVIRONMENT; NEOVASCULARIZATION (PATHOLOGY); NONPARAMETRIC TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; SPINDLE CELL; STROMA CELL; TISSUE DISTRIBUTION; TUMOR VASCULARIZATION; UVEA MELANOMA;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; IMMUNOENZYME TECHNIQUES; MATRIX METALLOPROTEINASES; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR MARKERS, BIOLOGICAL; UVEAL NEOPLASMS;

EID: 44649108198     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2008.03.010     Document Type: Article

References (34)

1. Baker J.K., Elshaw S.R., Mathewman G.E., Nichols C.E., Murray A.K., Parsons M.A., Rennie I.G., and Sisley K. Expression of integrins, degradative enzymes and their inhibitors in uveal melanoma: differences between in vitro and in vivo expression. Melanoma Res. 11 (2001) 265-273
2. Caudroy S., Polette M., Nawrocki-Raby B., Cao J., Toole B.P., Zucker S., and Birembaut P. EMMPRIN-mediated MMP regulation in tumor and endothelial cells. Clin. Exp. Metastasis 19 (2002) 697-702
3. Chirco R., Liu X.W., Jung K.K., and Kim H.R. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev. 25 (2006) 99-113
4. COMS. Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. COMS report no. 6. Am. J. Ophthalmol. 125 (1998) 745-766
5. El-Shabrawi Y., Ardjomand N., and Radner H. MMP-9 is predominantly expressed in epithelioid and not spindle cell uveal melanoma. J. Pathol. 194 (2001) 201-206
6. Folberg R., and Maniotis A.J. Vasculogenic mimicry. APMIS 112 (2004) 508-525
7. Folberg R., Pe'er J., Gruman L.M., Woolson R.F., Jeng G., Montague P.R., Moninger T.O., Yi H., and Moore K.C. The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: a matched case-control study. Human Pathol. 23 (1992) 1298-1305
8. Gambrelle J., Grange J.D., Devouassoux Shisheboran M., Rivoire M., Baggetto L.G., Jean-Louis B., Fleury J., and Kodjikian L. Survival after primary enucleation for choroidal melanoma: changes induced by the introduction of conservative therapies. Graefes Arch. Clin. Exp. Ophthalmol. 245 (2007) 657-663
9. Goldberg G.I., Strongin A., Collier I.E., Genrich L.T., and Marmer B.L. Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J. Biol. Chem. 267 (1992) 4583-4591
10. Gragoudas E.S., Egan K.M., Seddon J.M., Glynn R.J., Walsh S.M., Finn S.M., Munzenrider J.E., and Spar M.D. Survival of patients with metastases from uveal melanoma. Ophthalmology 98 (1991) 383-389
11. Handsley M.M., and Edwards D.R. Metalloproteinases and their inhibitors in tumor angiogenesis. Int. J. Cancer 115 (2005) 849-860
12. Hess A.R., Seftor E.A., Seftor R.E., and Hendrix M.J. Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res. 63 (2003) 4757-4762
13. Iida J., and McCarthy J.B. Expression of collagenase-1 (MMP-1) promotes melanoma growth through the generation of active transforming growth factor-beta. Melanoma Res. 17 (2007) 205-213
14. Jager M.J., Niederkorn J.Y., and Ksander B.R. Uveal Melanoma: a Model for Exploring Fundamental Cancer Biology (2004), Taylor & Francis Group plc, The Netherlands, Lisse
15. Kanekura T., Chen X., and Kanzaki T. Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int. J. Cancer 99 (2002) 520-528
16. Lambert E., Dasse E., Haye B., and Petitfrere E. TIMPs as multifacial proteins. Crit. Rev. Oncol. Hematol. 49 (2004) 187-198
17. Laver N.V. Uveal malignant melanoma and tissue metalloproteinase profiles. Invest. Ophthalmol. Vis. Sci. 43 (2002) E-abstract 1118
18. Maatta M., Tervahartiala T., Kaarniranta K., Tang Y., Yan L., Tuukkanen J., and Sorsa T. Immunolocalization of EMMPRIN (CD147) in the human eye and detection of soluble form of EMMPRIN in ocular fluids. Curr. Eye Res. 31 (2006) 917-924
19. Madigan M.C., Jager M.J., Lai K., and Conway R.M. EMMPRIN, a matrix metalloproteinase (MMP) inducer, is expressed in uveal melanomas. Ophthalmic Res. 35 Suppl. 1 (2003) 217
20. Maniotis A.J., Folberg R., Hess A., Seftor E.A., Gardner L.M., Pe'er J., Trent J.M., Meltzer P.S., and Hendrix M.J. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol. 155 (1999) 739-752
21. Nagase H., Visse R., and Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 69 (2006) 562-573
22. Nareyeck G., Zeschnigk M., von der Haar D., Schilling H., Bornfeld N., and Anastassiou G. Differential expression of tissue inhibitor of matrix metalloproteinases 3 in uveal melanoma. Ophthalmic Res. 37 (2005) 23-28
23. Raffetto J.D., and Khalil R.A. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem. Pharmacol. 75 (2008) 346-359
24. Rao R.A., Stoleru M.A., Laver N.V., and McLean I.W. Matrix metalloproteinases in uveal malignant melanoma: computer-based morphometric analysis. Invest. Ophthalmol. Vis. Sci. 45 (2004) E-abstract 1198
25. Sameshima T., Nabeshima K., Toole B.P., Yokogami K., Okada Y., Goya T., Koono M., and Wakisaka S. Glioma cell extracellular matrix metalloproteinase inducer (EMMPRIN) (CD147) stimulates production of membrane-type matrix metalloproteinases and activated gelatinase A in co-cultures with brain-derived fibroblasts. Cancer Lett. 157 (2000) 177-184
26. Seddon J., Egan K., and Gragoudas E. Epidemiology of uveal melanoma. Retina 1 (1994) 717-723
27. Seftor R.E., Seftor E.A., Koshikawa N., Meltzer P.S., Gardner L.M., Bilban M., Stetler-Stevenson W.G., Quaranta V., and Hendrix M.J. Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res. 61 (2001) 6322-6327
28. Singh A.D., Sisley K., Xu Y., Li J., Faber P., Plummer S.J., Mudhar H.S., Rennie I.G., Kessler P.M., Casey G., and Williams B.G. Reduced expression of autotaxin predicts survival in uveal melanoma. Br. J. Ophthalmol. 91 (2007) 1385-1392
29. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Sem. Cancer Biol. 10 (2000) 415-433
30. Tang Y., Kesavan P., Nakada M.T., and Yan L. Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN. Mol. Cancer Res. 2 (2004) 73-80
31. Vaisanen A., Kallioinen M., von Dickhoff K., Laatikainen L., Hoyhtya M., and Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) immunoreactive protein-a new prognostic marker in uveal melanoma?. J. Pathol. 188 (1999) 56-62
32. Vajdic C.M., Kricker A., Giblin M., McKenzie J., Aitken J., Giles G.G., and Armstrong B.K. Incidence of ocular melanoma in Australia from 1990 to 1998. Int. J. Can. 105 (2003) 117-122
33. van der Velden P.A., Zuidervaart W., Hurks M.H., Pavey S., Ksander B.R., Krijgsman E., Frants R.R., Tensen C.P., Willemze R., Jager M.J., and Gruis N.A. Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development. Int. J. Cancer 106 (2003) 472-479
34. Visse R., and Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 92 (2003) 827-839